BioMark Recognizes and Supports The Lung Cancer Awareness Month

biomark recognizes and supports lung cancer awareness month

BioMark Recognizes and Supports the Lung Cancer Awareness Month

Vancouver, British Columbia – (Nov 10, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it recognizes and wanted to raise awareness of the challenges that come from a diagnosis of lung cancer. There are fundamental strides being made in both the early diagnosis and more effective therapeutic intervention that will better smooth the treatment journey for patients.

Throughout November and beyond, BioMark will be posting relevant short articles related to this fatal disease in different social media. The campaign aims to encourages both men and women to know their risks for lung cancer and to consider annual screenings to gain an advantage on the disease through earlier diagnosis.

“Since 2007, our mission and team commitment remain the same. Develop and commercialize innovative technologies that increase the accuracy of early-stage diagnosis of cancers. BioMark continues to be deeply involved in the development of a simple blood test that can help detect lung cancer at an early stage (Stage I and II) where the chance of being cured increases1. Working with dedicated researchers, leading clinicians, and more importantly patients, we are determined and motivated to positively impact lung cancer through early detection where survival is greatly improved. Our goal this month is not only to share information but to recognize and support individuals and groups who have helped to make a difference for lung cancer patients, caregivers, family and friends” says Rashid Bux, President and CEO.

Last year, lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths accounting for 18% of all cancer deaths2. There is also an imperative need to better understand and address disparities in ethnic and socioeconomic inequities in lung cancer that contribute to cancer incidence and mortality3. Low socioeconomic populations experience greater environmental exposures and subsequent increased lung cancer incidence and mortality4,5. Similarly, rurality leads to further disparities, as black individuals in rural areas have greater lung cancer incidence than those in urban areas6.

Make sure to follow and share our social media posts. By sharing information about lung cancer, you’ll help us inspire new hope and change the face of the disease.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess early treatment for hard to detect and treat cancers using liquid biopsy. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website and on the CSE website

  1. Zhang, L.; Zheng, J.; Ahmed, R.; Huang, G.; Reid, J.; Mandal, R.; Maksymuik, A.; Sitar, D.S.; Tappia, P.S.; Ramjiawan, B.; Joubert, P.; Russo, A.; Rolfo, C.D.; Wishart, D.S. A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection. Cancers 2020, 12, 622.
  2. Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021: 71: 209- 249.
  3. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212–236.
  4. Yang R, Cheung MC, Byrne MM, Huang Y, Nguyen D, Lally BE, et al. Do racial or socioeconomic disparities exist in lung cancer treatment? Cancer 2010; 116:2437–2447.
  5. Hovanec J, Siemiatycki J, Conway DI, Olsson A, Stücker I, Guida F, et al. Lung cancer and socioeconomic status in a pooled analysis of case-control studies. PLoS One 2018;13:e0192999.
  6. Houston KA, Mitchell KA, King J, White A, Ryan BM. Histologic lung cancer incidence rates and trends vary by race/ethnicity and residential county. J Thorac Oncol 2018; 13:497–509.
For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: [email protected]

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved the content of this press release.
Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
FSE: 20B

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.